Literature DB >> 29614245

Respiratory syncytial virus burden among adults during flu season: an underestimated pathology.

M Kestler1, P Muñoz2, M Mateos3, D Adrados3, E Bouza2.   

Abstract

BACKGROUND: Information on the role of respiratory syncytial virus (RSV) in adult patients with influenza-like syndrome is scarce. AIM: To assess the clinical characteristics of RSV in adult patients with respiratory manifestations during a regular influenza season.
METHODS: Prospective study in a tertiary Spanish hospital from December 2015 to February 2016. The study population included only adult patients with either community-acquired or hospital/healthcare-associated influenza-like illness, according to the European Centre for Disease Prevention and Control criteria. Samples were analysed using a rapid molecular assay (Xpert® Flu/RSV). RSV-positive patients were compared with a randomly negative control group and with an influenza-positive control group.
FINDINGS: Twelve hundred patients with influenza-like respiratory infection were included. Overall, 114 of the samples (9%) were positive for influenza and 95 (8%) were positive for RSV. When RSV-positive and influenza-positive patients were compared, RSV-positive patients were older (57.7 vs 48.9 years; P = 0.03), and their disease was more frequently healthcare-related (26/95, 27.3% vs 5/114, 1.7%; P < 0.001). They also had significantly more antibiotics prescribed (77/95, 81.0% vs 70/114, 61.4%; P < 0.001) and more frequently needed hospital admission (93/95, 97.8% vs 69/114, 60.5%; P < 0.001). Mortality was also significantly higher in RSV-positive patients (14/95, 14.7% vs 7/114, 6.1%; P = 0.04).
CONCLUSION: RSV is a major cause of moderate-to-severe respiratory infection during the influenza season; acquisition is frequently nosocomial or healthcare-related; and mortality is significantly higher than with influenza virus infection. The use of a rapid molecular test as a first-step diagnostic technique is necessary to ensure that isolation measures are implemented and that spread is prevented.
Copyright © 2018 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adults; Influenza; Respiratory syncytial virus; Viral pneumonia

Mesh:

Year:  2018        PMID: 29614245     DOI: 10.1016/j.jhin.2018.03.034

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  13 in total

Review 1.  Melittin: a venom-derived peptide with promising anti-viral properties.

Authors:  Hamed Memariani; Mojtaba Memariani; Hamideh Moravvej; Mohammad Shahidi-Dadras
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-17       Impact factor: 3.267

2.  Severity and mortality of respiratory syncytial virus vs influenza A infection in hospitalized adults in China.

Authors:  Yulin Zhang; Yeming Wang; Jiankang Zhao; Zhujia Xiong; Yanyan Fan; Wang Zhang; Xiaohui Zou; Chunlei Wang; Jiajing Han; Binbin Li; Binghuai Lu; Bin Cao
Journal:  Influenza Other Respir Viruses       Date:  2020-05-25       Impact factor: 4.380

Review 3.  Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Gisela Canedo-Marroquín; Magdalena S Pizarro-Ortega; Catalina Andrade-Parra; Felipe Gómez-Santander; Alexis M Kalergis
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

4.  Characteristics of hospitalized adult patients with laboratory documented Influenza A, B and Respiratory Syncytial Virus - A single center retrospective observational study.

Authors:  Regev Cohen; Frida Babushkin; Keren Geller; Talya Finn
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

5.  Impact of molecular point-of-care testing on clinical management and in-hospital costs of patients suspected of influenza or RSV infection: a modeling study.

Authors:  Janette Rahamat-Langendoen; Hans Groenewoud; Judith Kuijpers; Willem J G Melchers; Gert Jan van der Wilt
Journal:  J Med Virol       Date:  2019-04-14       Impact factor: 2.327

6.  Comparison of clinical characteristics and outcomes between respiratory syncytial virus and influenza-related pneumonia in China from 2013 to 2019.

Authors:  Liang Chen; Xiudi Han; YanLi Li; Chunxiao Zhang; Xiqian Xing
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-06       Impact factor: 3.267

7.  Etiology of viral respiratory tract infections in hospitalized adults, and evidence of the high frequency of prehospitalization antibiotic treatment in Norway.

Authors:  Sara Debes; Jon Birger Haug; Birgitte Freiesleben de Blasio; Christine Monceyron Jonassen; Susanne Gjeruldsen Dudman
Journal:  Health Sci Rep       Date:  2021-10-08

8.  Influenza and respiratory syncytial virus during the COVID-19 pandemic: Time for a new paradigm?

Authors:  Emma Binns; Marianne Koenraads; Lidia Hristeva; Alix Flamant; Sebastian Baier-Grabner; Mervin Loi; Johanna Lempainen; Elise Osterheld; Bazlin Ramly; Jessica Chakakala-Chaziya; Niveditha Enaganthi; Silvia Simó Nebot; Danilo Buonsenso
Journal:  Pediatr Pulmonol       Date:  2021-10-13

9.  Systematic review on respiratory syncytial virus epidemiology in adults and the elderly in Latin America.

Authors:  Abraham Ali; Gustavo Lopardo; Bruno Scarpellini; Renato T Stein; Diogo Ribeiro
Journal:  Int J Infect Dis       Date:  2019-10-25       Impact factor: 3.623

10.  Preventing respiratory syncytial virus infections in hospitalized children and adults: should we do better?

Authors:  Pierre Frange; Julie Toubiana; Perrine Parize; Florence Moulin; Anne Scemla; Marianne Leruez-Ville
Journal:  Infect Prev Pract       Date:  2020-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.